Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Age ≥ 18 years, all genders, and ethnic origins
Free, informed, and written consent signed
Person affiliated to or benefiting from a social security scheme
Age < 18 years
Lack of informed consent
Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups)
Persons under administrative or judicial protection